Olema Pharmaceuticals, Inc.
OLMANASDAQHealthcare● Active
$10.00
$-0.32(-3.06%)
Market Cap$873037973
P/E Ratio—
52W High$36.259
52W Low$3.89
Olema Pharmaceuticals, Inc. (OLMA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OLMA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.52
Est. -$0.52 · +0.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
OLMA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.53 | — | — | — | — | — |
| — Q2 FY2026 | May 12, 2026 | -$0.52 | -$0.52 | +0.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 16, 2026 | -$0.51 | -$0.50 | +2.0% | — | — | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.44 | -$0.49 | -11.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.43 | -$0.51 | -18.6% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.49 | -$0.36 | +26.5% | — | — | — |
| ▲ Q1 FY2025 | Mar 18, 2025 | -$0.63 | -$0.51 | +19.1% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.59 | -$0.60 | -1.7% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.53
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026
EPS Actual
-$0.52
EPS Est.
-$0.52
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 16, 2026Beat
EPS Actual
-$0.50
EPS Est.
-$0.51
EPS Surpr.
+2.0%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.49
EPS Est.
-$0.44
EPS Surpr.
-11.4%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.51
EPS Est.
-$0.43
EPS Surpr.
-18.6%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.49
EPS Surpr.
+26.5%
Revenue
—
Q1 FY2025
Mar 18, 2025Beat
EPS Actual
-$0.51
EPS Est.
-$0.63
EPS Surpr.
+19.1%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.60
EPS Est.
-$0.59
EPS Surpr.
-1.7%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.52 | $-0.52 | $-0.52 | 6 |
| Q3 FY2027 | $-0.55 | $-0.55 | $-0.55 | 3 |
| Q2 FY2027 | $-0.56 | $-0.56 | $-0.56 | 5 |
| Q1 FY2027 | $-0.55 | $-0.55 | $-0.55 | 3 |
| Q4 FY2026 | $-0.58 | $-0.58 | $-0.58 | 6 |
| Q3 FY2026 | $-0.63 | $-0.56 | $-0.50 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +0.0% | $14.86 | $13.97 | -5.99% |
| ▲ Q1 FY2026 | Mar 16, 2026 | +2.0% | $14.71 | $16.60 | +12.85% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -11.4% | $8.35 | $8.70 | +4.19% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -18.6% | $4.64 | $4.57 | -1.51% |
| ▲ Q2 FY2025 | May 13, 2025 | +26.5% | $4.76 | $4.68 | -1.68% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +19.1% | $4.45 | $4.14 | -6.97% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -1.7% | $12.72 | $11.54 | -9.28% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +0.0% | $13.87 | $13.94 | +0.50% |
Q2 FY2026-5.99%
Report Date
May 12, 2026
EPS Beat/Miss
+0.0%
Price Before
$14.86
Price After
$13.97
Q1 FY2026+12.85%
Report Date
Mar 16, 2026
EPS Beat/Miss
+2.0%
Price Before
$14.71
Price After
$16.60
Q4 FY2025+4.19%
Report Date
Nov 10, 2025
EPS Beat/Miss
-11.4%
Price Before
$8.35
Price After
$8.70
Q3 FY2025-1.51%
Report Date
Aug 11, 2025
EPS Beat/Miss
-18.6%
Price Before
$4.64
Price After
$4.57
Q2 FY2025-1.68%
Report Date
May 13, 2025
EPS Beat/Miss
+26.5%
Price Before
$4.76
Price After
$4.68
Q1 FY2025-6.97%
Report Date
Mar 18, 2025
EPS Beat/Miss
+19.1%
Price Before
$4.45
Price After
$4.14
Q4 FY2024-9.28%
Report Date
Nov 12, 2024
EPS Beat/Miss
-1.7%
Price Before
$12.72
Price After
$11.54
Q3 FY2024+0.50%
Report Date
Aug 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$13.87
Price After
$13.94
Avg Beat Reaction-0.26%
Avg Miss Reaction-2.20%
Beat Rate5 / 8 quarters
Largest Move+12.85% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OLMA ends December
Olema Pharmaceuticals, Inc. (OLMA) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.52 (in line with the analyst consensus of $-0.52). OLMA has beaten EPS estimates for 2 consecutive quarters. The next OLMA earnings date is expected around September 1, 2026.
Each quarter, investors track OLMA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OLMA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OLMA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OLMA earnings · 4 questionsOlema Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. OLMA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OLMA historically reports after market close (AMC).
OLMA earnings datewhen is OLMA earningsOLMA next earnings datewhen does OLMA report earningsOLMA earnings calendar
▸ Source: FMP · Olema Pharmaceuticals, Inc. SEC filings · US GAAP · Olema Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026